UCSF Neurological Surgery faculty since 1994
Dr. Lamborn, a biostatistician, works with Brain Tumor Research Center (BTRC) investigators and trainees in the design and analysis of BTRC research studies - in particular for all clinical trials planned with the BTRC, but also for retrospective reviews based on the BTRC's clinical database, studies using animal models, and in vitro research. Trainees in Neurological Surgery receive biostatistical assistance and training through all of these mechanisms. In addition, Dr. Lamborn provides consultation on statistical issues related to review of the published literature, both through formal sessions on Evidence-Based Medicine presented in conjunction with Dr. Susan Chang and on an ad hoc basis, as requested.
Biostatistics and research design
Dr. Lamborn, a co-investigator on many funded BTRC research projects, provides biostatistical input into the design, analysis, and reporting of these studies. Laboratory projects include research using in vitro and animal models. Clinical projects include evaluation of predictive/prognostic factors, including tumor markers, as well as clinical trials. She has also served as Co-Director of the BTRC Tissue Bank, and has recently completed a 6-year term as Director of the UCSF Cancer Center Biostatistics Core.
Dr. Lamborn's primary research interest is to utilize statistical methodology to improve the design of experiments and to improve and adapt statistical techniques for use in data analysis and presentation. This research is targeted to address the needs of the specific research projects ongoing within the BTRC, both preclinical and clinical. The goal is efficient trials directly addressing the primary scientific questions in a way that is economical in terms of sample size and time required to complete all components of the study. In addition to the general statistical research effort described above, a substantial effort is ongoing to do research on prognostic factors using the data from the large database containing information on patients treated on clinical trials within the BTRC. Knowledge of prognostic factors will allow improvement of prospective clinical trial study design as well as increasing our ability to interpret results at the time of analysis.
Education, Training, and Previous Positions
1966: BA, Mathematics, Oberlin College
1968: MS, Statistics, Stanford University
1970: PhD, Statistics, Stanford University
1970-1974: Assistant Professor of Community Medicine and Mathematics, University of Vermont
1972-1974: Director of Biometry Facility and Biostatistics Masters Degree Program, University of Vermont
1974-1988: Upjohn Company
1988-1993: Northern California Cancer Center, Assistant Director, Biostatistical Consulting Shared Resource
1990-present: Quintiles Pacific, currently Senior Scientific Consultant
1996-present: Director, Cancer Center Biostatistics Core, UCSF
Selected Professional Memberships and Appointments
American Statistical Association
Biometric Society
Society for Clinical Trials
American Society of Clinical Oncology
American Association for Cancer Research
Society for Neuro-Oncology
Selected Honors and Awards
Fellow, American Statistical Association
Magna Cum Laude, Oberlin College
Sigma Xi
Phi Beta Kappa
Woodrow Wilson Fellow
Contact
Kathleen R. Lamborn PhD
University of California, San Francisco
Department of Neurological Surgery
400 Parnassus Ave., A808
San Francisco, CA 94143-00372
Phone: (415) 353-2383
Selected Recent Publications
Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008;108(2):227-35.
Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, Deangelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD; for the North American Brain Tumor Consortium and the National Cancer Institute. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 2007;13(24):7401-6.
Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, Nelson SJ, Dillon WP. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28(6):1078-84.
Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol 2007;9(2):82-8.
Koo MS, Ozawa T, Santos RA, Lamborn KR, Bollen AW, Deen DF, Kahl SB. Synthesis and comparative toxicology of a series of polyhedral borane anion-substituted tetraphenyl porphyrins. J Med Chem 2007;50(4):820-7.
Yoo H, Baia GS, Smith JS, McDermott MW, Bollen AW, Vandenberg SR, Lamborn KR, Lal A. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res 2007;13(1):68-75.
Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007;81(3):271-7.
Ozawa T, Faddegon BA, Hu LJ, Bollen AW, Lamborn KR, Deen DF. Response of intracerebral human glioblastoma xenografts to multifraction radiation exposures. Int J Radiat Oncol Biol Phys 2006;66(1):263-70.
Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006;24(22):3651-6.
Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 2006;105(1):34-40.
Mishra KK, Puri DR, Missett BT, Lamborn KR, Prados MD, Berger MS, Banerjee A, Gupta N, Wara WM, Haas-Kogan DA. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro Oncol 2006;8(2):166-74.
Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J; North American Brain Tumor Consortium. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006;8(2):189-93.
Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol 2006;37(3):272-82.
Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape K, Lamborn KR, Parsa AT, Sison JD, Prados MD. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 2006;66(8):4531-41.
Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006;8(1):67-78.
Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, Prados MD. Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol 2006;8(1):12-26.
Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005;11(21):7841-50.
Gomez DR, Missett BT, Wara WM, Lamborn KR, Prados MD, Chang S, Berger MS, Haas-Kogan DA. High failure rate in spinal ependymomas with long-term follow-up. Neuro Oncol 2005;7(3):254-9.
Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol 2005;7(4):425-34.
Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD; North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23(4):357-61.
Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2005;23(27):6647-56.
Lu Y, Jin H, Lamborn KR. A design of phase II cancer trials using total and complete response endpoints. Stat Med 2005;24(20):3155-70.
Misra A, Pellarin M, Hu L, Kunwar S, Perhouse M, Lamborn KR, Deen DF, Feuerstein BG. Chromosome transfer experiments link regions on chromosome 7 to radiation resistance in human glioblastoma multiforme. Genes Chromosomes Cancer 2006;45(1):20-30.
Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97(12):880-7.
Ozawa T, Afzal J, Lamborn KR, Bollen AW, Bauer WF, Koo MS, Kahl SB, Deen DF. Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model. Int J Radiat Oncol Biol Phys 2005;63(1):247-52.
Misra A, Pellarin M, Nigro J, Smirnov I, Moore D, Lamborn KR, Pinkel D, Albertson DG, Feuerstein BG. Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 2005;11(8):2907-18.
Ozawa T, Hu JL, Hu LJ, Kong EL, Bollen AW, Lamborn KR, Deen DF. Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model. Cancer Gene Ther 2005;12(5):449-55.
Quiñones-Hinojosa A, Lyon R, Zada G, Lamborn KR, Gupta N, Parsa AT, McDermott MW, Weinstein PR. Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function. Neurosurgery 2005;56(5):982-93; discussion 982-93.
Parsa AT, Wachhorst S, Lamborn KR, Prados MD, McDermott MW, Berger MS, Chang SM. Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 2005;102(4):622-8.
Chen JK, Hu LJ, Wang J, Lamborn KR, Kong EL, Deen DF. Hypoxia-induced BAX overexpression and radiation killing of hypoxic glioblastoma cells. Radiat Res 2005;163(6):644-53.
Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005;102(16):5814-9.
Wang D, Ruan H, Hu L, Lamborn KR, Kong EL, Rehemtulla A, Deen DF. Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. Cancer Gene Ther 2005;12(3):276-83.
Butowski N, Prados MD, Lamborn KR, Larson DA, Sneed PK, Wara WM, Malec M, Rabbitt J, Page M, Chang SM. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 2005;61(5):1454-9.
Ozawa T, Gryaznov SM, Hu LJ, Pongracz K, Santos RA, Bollen AW, Lamborn KR, Deen DF. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol 2004;6(3):218-26.
Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004;6(3):227-35.
Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004;60(2):353-7.
Chang SM, Lamborn KR, Malec M, Rabbitt J, Page M, Prados MD. Phase II study of salvage therapy with high-dose tamoxifen and oral etoposide for recurrent malignant glioma. Therapy 2004;1(1):53-60.
Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004;100(1):41-6.
Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 2004;6(2):119-26.
Papavassiliou E, Rau G, Heath S, Abosch A, Barbaro NM, Larson PS, Lamborn K, Starr PA. Thalamic deep brain stimulation for essential tremor: relation of lead location to outcome. Neurosurgery 2004;54(5):1120-29; discussion 1129-30.
Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004;100(3):605-11.
